TRPC3 and cardiac hypertrophy: It is noteworthy that specific inhibition of TRPC3 prevented Ca2+-dependent activation of NFAT [154], which precedes cardiac hypertrophy and fibrosis, suggesting TRPC3 channels as novel drug targets to prevent cardiac fibrosis in the human heart.